Dypha: adding the dimension of time to cell culture

The δypha System aims to enhance drug development by providing a plug-and-play microfluidic adaptor for 96 well plates, enabling precise control of fluid kinetics in cell culture models.

Subsidie
€ 2.499.625
2024

Projectdetails

Introduction

The current preclinical drug development pipeline is highly inefficient with 9 out of 10 drugs failing when first tested in humans. Of those failures, between 69% and 81% is due to a lack of efficacy (52-57%) or safety (17-24%), indicating that the predictivity of currently used cell culture and animal models is not high enough.

Limitations of Current Models

While promising human cell culture models have arisen in the last decades (e.g. pluripotent stem cell models, spheroids, organoids), the environment of these models is too simplistic to reach their full potential and to translate certain responses to humans.

Kinetics in Cell Culture

One of the important aspects missing in current cell culture is kinetics: many processes in the human body have response times with resolutions of seconds, minutes, or hours. In standard cell culture, however, such temporal resolution is absent because cell culture medium remains unchanged for typically 1-3 days.

Challenges with Animal Models

For kinetics, scientists turn to animal models with relatively low translational success and high costs.

Alternative Solutions

As an alternative, complex microfluidic setups have been used to enable perfusion in vitro and demonstrated a significant amount of evidence that kinetics can improve the relevance of cell culture models. Despite the evidence, typical cell culture biologists are not taking kinetics into account because the tools to control kinetics in cell culture are too complex.

Our Solution

We solve this problem by starting from what cell culture biologists currently use: a standard well plate. We developed a µFluidic Adaptor that can be clamped on any 96 well plate and completely replaces the fluid in the well homogenously without disturbing the cell culture.

Goals and System Overview

Our goal is to develop a plug-and-play peripheral system that integrates automated fluidics and microscopic readout in a fully controlled environment: the δypha System. The system uses µFluidic Adaptors that can be designed for different applications or well plate formats.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.499.625
Totale projectbegroting€ 2.499.625

Tijdlijn

Startdatum1-4-2024
Einddatum31-3-2027
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • DEMCON SYNC BIOSYSTEMS BVpenvoerder
  • ESQLABS GMBH
  • OSPEDALE PEDIATRICO BAMBINO GESU
  • PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV
  • CHARLES RIVER NEDERLAND BV
  • DEMCON LIFE SCIENCES & HEALTH ENSCHEDE BV

Land(en)

NetherlandsGermanyItaly

Vergelijkbare projecten binnen EIC Transition

EIC Transition

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

€ 1.457.500
EIC Transition

Prefabricated Mature Blood Vessels and Tools for Vascularized 3D Cell Culture

The Vasc-on-Demand project aims to develop three innovative products for easy generation of vascularized 3D tissues, enhancing research and drug testing while reducing reliance on animal trials.

€ 2.488.750
EIC Transition

IDEFIX Multiorgan toxicity and efficacy test platform

Cherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions.

€ 2.496.073

Vergelijkbare projecten uit andere regelingen

ERC Proof of...

High-throughput combinatory drugs testing on in vitro 3D cells model platform

The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.

€ 150.000
EIC Accelerator

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development

Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.

€ 2.499.831
ERC Proof of...

High Throughput Modelling and Measurement of Human Epithelial Models using Electrospun Conducting Polymers For Unlocking Data-Driven Drug Discovery

The project aims to enhance drug discovery by developing simplified Organ on Chip platforms through hydrogel electrospinning, enabling scalable monitoring and integration into industry workflows.

€ 150.000
ERC Proof of...

High-throughput production of anisotropic 3D human tissue models

Developing a magnetic hydrogel system to create 3D tissue models that accurately mimic human tissue architecture, enhancing drug discovery and personalized medicine efficiency.

€ 150.000
ERC Proof of...

Biomimetic Sensorized Barriers-on-a-Chip: Unveiling a new Generation of Market-Ready Investigation Tools

This project aims to validate a novel, dynamic blood-brain barrier model with sensing features for improved drug screening in CNS pathologies, reducing reliance on animal testing and clinical trial failures.

€ 150.000